Journal of Physiology & Pathology in Korean Medicine (동의생리병리학회지)

The Physiological Society of Korean Medicine and The Society of Pathology in Korean Medicine (대한동의생리학회·한의병리학회)
권호 표지

Investigation Synergism of Eunkyo-san, a Poly-herbal Formula and Ciprofloxacin against Streptococcus pneumoniae Respiratory Infection

은교산과 Ciprofloxacin의 병용투여가 Streptococcus pneumoniae 호흡기감염에 미치는 영향

  • Lee, Sang-Jun (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University) ;
  • Jeon, Kwi-Ok (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University) ;
  • Song, Kwang-Kyu (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University) ;
  • Choi, Hae-Yun (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University) ;
  • Kim, Jong-Dae (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University)
  • 이상준 (대구한의대 한의학과 폐계내과학교실) ;
  • 전귀옥 (대구한의대 한의학과 폐계내과학교실) ;
  • 송광규 (대구한의대 한의학과 폐계내과학교실) ;
  • 최해윤 (대구한의대 한의학과 폐계내과학교실) ;
  • 김종대 (대구한의대 한의학과 폐계내과학교실)
  • Published : 2005.08.01
Download PDF
⟨ Previous Next ⟩

Abstract

In order to evaluate the in vivo synergic effect of Eunkyo-san which was a traditional poly-herbal formula has been used in the treatment of respiratory diseases in Korea, with quinolone antibiotics, ciprofloxacin (CPFX), the viable bacterial number and histopathological changes were monitored after experimental respiratory infection with S. pneumoniae ATCC 6303. The obtained results were as follows: In CPFX groups, the viable bacterial numbers were significantly decreased compared to that of control group and these were more dramatically decreased compared to that of single treatment with CPFX, respectively in concomitant treated groups with Eunkyo-san. In control group, severe infiltration of inflammatory cells, hemorrhage and hypertrophy of alveolar linings were demonstrated at microscopical levels. However, these abnormal histopathological changes were significantly decreased compared to that of control group in CPFX groups, and these were more dramatically decreased compared to that of single treatment with CPFX, respectively in concomitant treated groups with Eunkyo-san. In CPFX groups, the LSA (luminal surface of alveoli $\%$) were significantly increased compared to that of control group and these were more dramatically decreased compared to that of single treatment with CPFX, respectively in concomitant treated groups with Eunkyo-san. According to these results, it is considered as the in vivo antibacterial activity of CPFX was dramatically increased by concomitant use of Eunkyo-san against S. pneumoniae ATCC 6303 infection of respiratory tract.

Keywords

References

  1. Gordon, R.C. Community-acquired pneumonia in adolescents. Adolesc Med 11(3):681-695, 2000.
  2. File, T.M. The epidemiology of respiratory tract infections. Semin Respir Infect 15(3):184-294, 2000.
  3. Roos, K.L. Acute bacterial meningitis. Semin Neurol 20(3): 293-306, 2000.
  4. Moreillon, P., Wengner, A, Caldelari, I. Pneumococcal antibiotic resistance. Rev Med Suisse Romande 120, 651-659, 2000.
  5. Givner, L.B., Mason, E.O. Jr, Barson, W.J., Tan, T.Q., Wald, E.R, Schutze, G.E., Kim, KS., Bradley, J.5., Yogev, R, Kaplan, S.L. Pneumococcal facial cellulitis in children. Pediatrics 106(5), E61, 2000.
  6. Cosentini, R, Blasi, F. New pathogens for respiratory infections. Curr Opin Pulm Med 2(3):174-180, 1996.
  7. Ball, P. Quinolone generations: natural history or natural selection? J Antimicrob Chemother 46, 17-24, 2000.
  8. Farker, K., Naber, K.G., Funfstuck, R Fluoroquinolones: utilization in renal and urogenital tract infections. Med Klin 96, 383-390, 2001.
  9. Paladino, J.A. Is more than one quinolone needed in clinical practice? Ann Pharmacother 35(9):1085-1095, 2001.
  10. Rubinstein, E. History of quinolones and their side effects. Chemotherapy 47, 3-8, 2001.
  11. Ball, P. Future of the quinolones. Semin Respir Infect 16(3): 215-224, 2001.
  12. Fitzgibbon, J.E., Nahvi, M.D., Dubin, D.T., John, J.F. Jr. A sequence variant of Staphylococcus hominis with a high prevalence of oxacillin and fluoroquinolone resistance. Res Microbiol 152(9):805-810, 2001.
  13. Bachoual, R., Ouabdesselam, S., Mory, F., Lascols, C., Soussy, C.J., Tankovic, J. Single or double mutational alterations of gyrA associated with fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli.Microb Drug Resist 7(3):257-261, 2001.
  14. Hakanen, A., Kotilainen, P., Huovinen, P., Helenius, H., Siitonen, A Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from Southeast Asia. Emerg Infect Dis 7(6):996-1003, 2001.
  15. Janoir, C. Varon, E., Kitzis, M.D., Gutmann, L. New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones. Antimicrob Agents Chemother 45(3):952-955, 2001.
  16. Ruiz, J., Sierra, J.M., De Anta, M.T., Vila, J. Characterization of sparfloxacin-resistant mutants of Staphylococcus aureus obtained in vitro. Int J Antimicrob Agents 18(2):107-112, 2001.
  17. Appelbaum, P.C., Hunter, P.A. The fluoroquinolone antibacterials : past, present and future perspectives. Int J Antimicrob Agents 16(1):5-15, 2000.
  18. Bergan, T. Extravascular penetration of ciprofloxacin. A review Diagn Microbiol Infect Dis 13, 103-114, 1990.
  19. Joyanes. P., Pascual, A., Gimenez, M.J., Garcia, I., Aguilar, L., Perea, E. Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae. Chemotheraphy 47(6):409-414, 2001.
  20. Weller, T.M., Andrews, J.M., [evens, G., Wise, R The in vitro activity of BM-284756, a new des-fluorinated quinolone. J Antimicrob Chemother 49(1):177-184, 2002.
  21. Stahlmann, R, Lode, H. Toxicity of quinolones. Drugs 58, 37-42, 1999.
  22. Cunha, B.A Antibiotic resistance. Med Clin North Am 84(6):1407-1429, 2000.
  23. McGee, L., Goldsmith, C.E., Klugman, K.P. Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones. J Antinicrob Chemother. 49(1):173-176, 2002.
  24. Lopez, A., Hudson, J.B., Towers, G.H. Antiviral and antimicrobial activities of Colombian medicinal plants. J Ethnopharmacol 77(2):189-196, 2001.
  25. Elgayyar, M., Draughon, F.A., Golden, D.A., Mount, J.R. Antimicrobial activity of essential oils from plants against selected pathogenic and saprophytic microorganisms. J Food Prot 64(7):1019-1024, 2001.
  26. Ho, K.Y., Tsai, C.C., Chen, C.P., Huang, J.S., Lin, C.C Antimicrobial activity of honokiol and magnolol isolated from Magnolia officinalis. Phytother Res 15(2):139-141, 2001.
  27. Ojala, T., Remes, S., Haansuu, P., Vuorela, H., Hiltunen, R., Haahtela, K., Vuorela, P. Antimicrobial activity of some coumarin containing herbal plants growing in Finland. J Ethnopharmacol 73(1-2):299-305, 2000.
  28. Satoh, K, Sakagami, H., Ida, Y., Komatsu, N., Fujimaki, M., Nakashima, H., Kanbara, K, Gupta, M., Sarma, D.N., Mitra, S.K. Antimicrobial and radical modulation activity of AV-07, a poly-herbal formula. In Vivo 14(2):351-355, 2000.
  29. Mahasneh, A.M., El-Oqlah, A.A. Antimicrobial activity of extracts of herbal plants used in the traditional medicine of Jordan. J Ethnopharmacol 64(3):271-276, 1999.
  30. Desta, B. Ethiopian traditional herbal drugs. Part II: Antimicrobial activity of 63 medicinal plants. Ethnopharmacol 39(2):129-139, 1993.
  31. Van Puyvelde, L., Geiser, I., Rwangabo, P.C, Sebikali, B. Rwandese herbal remedies used against gonorrhoea. J Ethnopharmacol 8(3):279-286, 1983.
  32. Kim, C.M., Heo, M.Y., Kim, H.P., Shin, K.S., Pachaly P. Pharmacological activities of water extracts of Umbelliferae plants. Arch Pharm Res 14, 87-92, 1991.
  33. 全國韓醫科大學肺系內科學敎室編著. 東醫肺系內科學. p.85, 98, 140, 263, 282, 311, 한문화사, 서울, 2002.
  34. 김상찬, 김선희외 9명. 방제학. 영림사, 서울, p 83-84, 1999.
  35. 楊進 編. 溫病條辦. 中國醫藥科技出版社, 北京, 1996.
  36. 韓鏞微. 임상호흡기학. 一朝閣, 서울, p 139, 146, 47-81, 1997.
  37. Gillespie, S.H., Morrissey, I., Everett, D. A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model. J Med Microbiol 50(6): 565-570, 2001.
  38. Berry, V., Page, R., Satterfield, J., Singley, C., Straub, R., Woodnutt, G. Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection. J Antimicrob Chemother 45, 79-85, 2000.
  39. Onyeji, C.O., BUi, K.Q., Owens, R.C. Jr, Nicolau, D.P., Quintiliani, R., Nightingale, C.H. Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. Int J Antirnicrob Agents 12(2):107-114, 1999.
  40. Martinez, F.F., Carabias, M.L., Izquierdo, J.I., Centelles, M.L., Prieto, J.P. Comparison of the in vitro and in vivo effects of meropenem and ciprofloxacin on the morphology of Escherichia coli and Staphylococcus aureus. Rev Esp Quimioter 11(3):238-244, 1998.
  41. Nau, R., Schmidt, T., Kaye, K., Froula, J.L., Tauber, M.G. Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother 39(3):593-597, 1995.
  42. Lin, R., Holland, G.N., Helm, C.J., Elias, S.J., Berlin, O.G., Bruckner, D.A. Comparative efficacy of topical ciprofloxacin for treating Mycobacterium fortuitum and Mycobacterium chelonae keratitis in an animal model. Am J Ophthalmol 117(5):657-662, 1994.
  43. Mattie, H., Hoogeterp, J.J., Terporten, P. The activity of ciprofloxacin against Pseudomonas aeruginosa in normal and granulocytopenic mice. Pharm Weekbl Sci 11, 526-529, 1987.
  44. Roosendaal, R., Bakker-Woundenberg, I.A., van den Berghe-van Raffe M., Vink-van den Berg, J.C, Michel, M.F. Comparative activities of ciprofloxacin and ceftazidime against Klensiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats. Antimicrob Agents Chemother 31(11):1809-1815, 1987.